Monoclonal antibodies Leu 11a (CD16) and Leu 19 (CD56) were tested for
reactivity with cells from 36 patients with acute myelogenous leukemi
a (AML) using two-colour flow cytometry. Blast cells were identified b
y a broad panel of monoclonal antibodies. In 33% (12/36) the monoclona
l antibody Leu 19, which has been demonstrated to bind to the 140 kD i
soform of the human neural cellular adhesion molecule N-CAM, found on
peripheral natural killer (NK)-cells, neuroectodermal cells, activated
T-cells, and myeloma cells, was shown to bind strongly to the leukemi
c cells. The monoclonal antibody Leu 11a, which recognizes a surface d
ifferentiation antigen associated with the low affinity FcRIII for IgG
, expressed on NK-cells, granulocytes and macrophages were found to bi
nd to leukemic cells of four of the 12 Leu-19 positive cases. 50% (6/1
2) of Leu-19 positive patients were classified as having M4 according
to the French-American-British (FAB) morphology criteria. The potentia
l diagnostic and clinical importance of CD 56 and/or CD 16 expression
in acute myelogenous leukemia is presently under investigation.